Zafgen
develops and commercializes novel therapeutics for the treatment of type 2 diabetes, obesity and related disorders... Read moreZafgen
develops and commercializes novel therapeutics for the treatment of type 2 diabetes, obesity and related disorders... Read more
2005
PublicSubsidiary of Larimar TherapeuticsNASDAQZFGN
News
May 09, 2024
Marketscreener
Zafgen: Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Mar 15, 2023
Owler
Larimar Therapeutics, Inc.: Zafgen's employee count changed from 25 in Dec 2021 to 26 in Dec 2022
May 29, 2020
The Business Journals: Philadelphia
Zafgen: Montgomery County biotech firm completes reverse merger, raises $77.8 million
May 29, 2020
The Pharma Letter
Zafgen: BRIEF-Chondrial Therapeutics and Zafgen complete merger
Apr 24, 2020
Market Exclusive
Zafgen: Zafgen, Inc. (NASDAQ:ZFGN) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Mar 09, 2020
MarketScreener
Zafgen: Zafgen : SEC Filing (DEFA14A)
Mar 09, 2020
Market Exclusive
Zafgen: Zafgen, Inc. (NASDAQ:ZFGN) Files An 8-K Entry into a Material Definitive Agreement
Mar 05, 2020
BioSpace
Zafgen: Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results
Mar 05, 2020
Seeking Alpha
Zafgen: Zafgen EPS in-line
Feb 05, 2020
Market Exclusive
Zafgen: Zafgen, Inc. (NASDAQ:ZFGN) Files An 8-K Regulation FD Disclosure
Zafgen Competitors
1
2
3
4
5
6
7
8
9
10